Terms: = Germ cell tumor AND LZTR1, ENSG00000099949, 8216, Q8N653, TCFL2, MGC21205, LZTR-1 AND Treatment
11 results:
1. WP1066 induces cell death in a schwannomatosis patient-derived schwannoma cell line.
Allaf A; Victoria B; Rosario R; Misztal C; Humayun Gultekin S; Dinh CT; Fernandez-Valle C
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35732500
[TBL] [Abstract] [Full Text] [Related]
2. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract] [Full Text] [Related]
3. ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis.
Evans DG; Mostaccioli S; Pang D; Fadzil O Connor M; Pittara M; Champollion N; Wolkenstein P; Thomas N; Ferner RE; Kalamarides M; Peyre M; Papi L; Legius E; Becerra JL; King A; Duff C; Stivaros S; Blanco I
Eur J Hum Genet; 2022 Jul; 30(7):812-817. PubMed ID: 35361920
[TBL] [Abstract] [Full Text] [Related]
4. Skull Base tumors: Neuropathology and Clinical Implications.
Bi WL; Santagata S
Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
[TBL] [Abstract] [Full Text] [Related]
5. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
[TBL] [Abstract] [Full Text] [Related]
6. Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling.
Chen Z; Li S; Mo J; Hawley E; Wang Y; He Y; Brosseau JP; Shipman T; Clapp DW; Carroll TJ; Le LQ
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32960816
[TBL] [Abstract] [Full Text] [Related]
7. Neurofibromatosis type 2 and related disorders.
Halliday D; Parry A; Evans DG
Curr Opin Oncol; 2019 Nov; 31(6):562-567. PubMed ID: 31425178
[TBL] [Abstract] [Full Text] [Related]
8. An update on the CNS manifestations of neurofibromatosis type 2.
Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
[TBL] [Abstract] [Full Text] [Related]
9. Oligo-astrocytoma in lztr1-related Noonan syndrome.
Jacquinet A; Bonnard A; Capri Y; Martin D; Sadzot B; Bianchi E; Servais L; Sacré JP; Cavé H; Verloes A
Eur J Med Genet; 2020 Jan; 63(1):103617. PubMed ID: 30664951
[TBL] [Abstract] [Full Text] [Related]
10. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
[TBL] [Abstract] [Full Text] [Related]
11. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
Ruggieri M; Praticò AD; Evans DG
Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
[TBL] [Abstract] [Full Text] [Related]
